Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of NKTR is 121 and suggests 83% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell